Patent EP0613949A2 successfully refreshed from Google Patents.
EP0613949A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Gene encoding chondroitinase ABC and uses therefor
Assignee: Maruha Nichiro Corp
•
Filing: 1994-02-23
•
Granted: —
•
Expires: 2014-02-23
Abstract
Abstract Nucleic acid sequences coding for the chondroitinase ABC gene and isolated chondroitinase ABC protein produced in a host cell transformed with a nucleic acid vector directing the expression of a nucleotide sequence coding for chondroitinase ABC protein are described. Chondroitinase ABC prepared by chemical synthesis is also described. Monoclonal and polyclonal antibodies which are specifically reactive with chondroitinase ABC protein are disclosed. The isolated chondroitinase ABC can be used in methods of treating intervertebral disc displacement, promoting neurite regeneration, and detecting galactosaminoglycans.
Inventors
- 👤 Nobuyuki Sato
- 👤 Masahiko Shimada
- 👤 Hiroshi Oda
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 13:54
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/573; C; C12; C12N; C12N9/00; C12N9/88; C12Y; C12Y402/00; C12Y402/02; C12Y402/02004; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
12 words
An isolated nucleic acid having a nucleotide sequence coding for chondroitinase ABC.
Claim 2
Dependent Claim
21 words
An isolated nucleic acid of claim 1 wherein said nucleotide sequence consists essentially of the nucleotide sequence of SEQ ID NO:1.
Claim 3
Dependent Claim
25 words
An isolated nucleic acid having a nucleotide sequence coding for chondroitinase ABC, said nucleotide sequence consisting essentially of the nucleotide sequence of SEQ ID NO:1.
Claim 4
Dependent Claim
17 words
An expression vector comprising a nucleotide sequence coding for chondroitinase ABC operably linked to a regulatory sequence.
Claim 5
Dependent Claim
20 words
An expression vector of claim 4 wherein said nucleotide sequence consists essentially of the nucleotide sequence of SEQ ID NO:1.
Claim 6
Dependent Claim
7 words
A host cell transformed to express chondroitinase.
Claim 7
Dependent Claim
11 words
A host cell of claim 6 wherein the cell is eukaryotic.
Claim 8
Independent Claim
42 words
A method of producing chondroitinase ABC protein comprising: culturing a host cell transformed with a nucleic acid vector directing expression of a nucleotide sequence coding for chondroitinase ABC protein under conditions appropriate for expression, and isolating chondroitinase ABC protein from the culture.
Claim 9
Dependent Claim
4 words
Isolated chondroitinase ABC protein.
Claim 10
Dependent Claim
18 words
Isolated chondroitinase ABC protein of claim 9 consisting essentially of the amino acid sequence of SEQ ID NO:2.
Claim 11
Dependent Claim
10 words
A non-naturally occurring analogue of chondroitinase ABC which degrades chondroitin.
Claim 12
Dependent Claim
10 words
An antibody specifically reactive with the protein of claim 9.
Claim 13
Dependent Claim
13 words
An antibody of claim 12 which is a monoclonal or a polyclonal antibody.
Claim 14
Dependent Claim
20 words
An antibody specifically reactive with isolated chondroitinase ABC protein consisting essentially of an amino acid sequence of SEQ ID NO:2.
Claim 15
Dependent Claim
10 words
An antibody of claim 14 which is a monoclonal antibody.
Claim 16
Dependent Claim
35 words
A therapeutic composition comprising a therapeutically active amount of the protein of claim 9 and a pharmaceutically acceptable carrier or a therapeutically active amount of the protein of claim 10 and a pharmaceutically acceptable carrier.
Claim 17
Dependent Claim
45 words
A therapeutic composition for the treatment of intervertebral disc displacement in an individual comprising a therapeutically active amount of the protein of claim 9 and a pharmaceutically acceptable carrier or a therapeutically active amount of the protein of claim 10 and a pharmaceutically acceptable carrier.
Claim 18
Dependent Claim
32 words
A method for treating intervertebral disc displacement in an individual comprising administering into the intervertebral disc space of the individual a therapeutically effective amount of one of the compositions of claim 17.
Claim 19
Dependent Claim
23 words
The method of claim 18 wherein the therapeutically effective amount of the protein of claim 9 is about 100 units per human disc.
Claim 20
Dependent Claim
44 words
A therapeutic composition for the treatment of nerve damage in an individual comprising a therapeutically active amount of the protein of claim 9 and a pharmaceuticlly acceptable carrier or a therapeutically active amount of the protein of claim 10 and a pharmaceutically acceptable carrier.
Claim 21
Dependent Claim
30 words
A method of treating nerve damage in an individual comprising administering to the point of injury in the individual a therapeutic amount of one of the compositions of claim 20.
Claim 22
Dependent Claim
28 words
A diagnostic reagent for detecting the presence of a galactosaminoglycan in a mammalian tissue, the reagent comprising the protein of claim 9 or the protein of claim 10.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.